YRDC and sarcoma: We observed a significantly worse prognosis in patients with high YRDC expression compared to those with low YRDC expression in 12 tumor patients including adrenocortical carcinoma (ACC), LUAD, BRCA, bladder urothelial carcinoma (BLCA), HNSC, uterine carcinosarcoma (UCS), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), sarcoma (SARC), mesothelioma (MESO), brain lower grade glioma (LGG), kidney chromophobe (KICH), LIHC (p < 0.05, univariate Cox regression, Figures 3A and S2).